| Followers | 59 |
| Posts | 7590 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Friday, November 15, 2019 6:47:21 PM
Markipeach, Of course I always viewed AMRN as being a logical takeover
candidate in the evolution of Vascepa's development as a Cardiovascular
drug. If BP believes in Vascepa the way posters here in the GIA camp
believe in Vascepa's potential...well, it would be all over.
The market needs a generic settlement, which is most likely prior
to the scheduled trial date of Jan. 13. Before the end of December
the FDA should give us their label for the CVD indication. With
these two events the "takeover window" will be open. Whether or
not AMRN announces a partner for Europe may tell us the answer.
As long as no partner is announced it is then possible AMRN is
holding out for a takeout. If a partner is announced a takeover
is far less likely.
Given the multi-year record share price today I think investors are
buying because they believe a takeover is likely in the near term.
What I think does not matter. I am of the opinion that JT has his
"price" where he will take an offer to the BOD. My belief is that
Vascepa in the hands of BP will get Vascepa into the hands of patients
much faster and more broadly than AMRN by itself. That is how the
process works...like it or not.
candidate in the evolution of Vascepa's development as a Cardiovascular
drug. If BP believes in Vascepa the way posters here in the GIA camp
believe in Vascepa's potential...well, it would be all over.
The market needs a generic settlement, which is most likely prior
to the scheduled trial date of Jan. 13. Before the end of December
the FDA should give us their label for the CVD indication. With
these two events the "takeover window" will be open. Whether or
not AMRN announces a partner for Europe may tell us the answer.
As long as no partner is announced it is then possible AMRN is
holding out for a takeout. If a partner is announced a takeover
is far less likely.
Given the multi-year record share price today I think investors are
buying because they believe a takeover is likely in the near term.
What I think does not matter. I am of the opinion that JT has his
"price" where he will take an offer to the BOD. My belief is that
Vascepa in the hands of BP will get Vascepa into the hands of patients
much faster and more broadly than AMRN by itself. That is how the
process works...like it or not.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
